Get the Stockscreener App
1.37
2.14%
-0.03
After Hours:
1.39
0.02
+1.46%
Medicinova Inc stock is traded at $1.37, with a volume of 33,124.
It is down -2.14% in the last 24 hours and up +0.00% over the past month.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
33,124
Relative Volume:
0.76
Market Cap:
$67.43M
Revenue:
$409.70K
Net Income/Loss:
$-12.00M
P/E Ratio:
-5.6033
EPS:
-0.2445
Net Cash Flow:
$-9.81M
1W Performance:
-0.72%
1M Performance:
+0.00%
6M Performance:
-5.52%
1Y Performance:
-2.84%
1-Day Range:
$1.36
$1.40
1-Week Range:
$1.36
$1.45
52-Week Range:
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.37 | 68.91M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | H.C. Wainwright | Buy |
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesEarnings Cycle Outlook - Newser
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
MNOV Q1 2026 Earnings: Drug Development Progress Drives Narrower-than-Expected LossHigh Attention Stocks - Newser
MediciNova Inc stock (US58468P2038): biotech eyes IPF and neurology pipeline as investors watch next - AD HOC NEWS
MSN Money - MSN
MediciNova, Inc.Common Stock (NQ: MNOV - FinancialContent
MediciNova stock (US58468P2038): Earnings update after April study news - AD HOC NEWS
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo Finance
MediciNova Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MediciNova: Q1 Earnings Snapshot - KTVB
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MediciNova (MNOV) Q1 2026 results show lower loss and $27.3M cash - Stock Titan
Medici Nova Biotechnology (MNOV.US) will release its earnings report after the market closes on May 15. - Moomoo
MediciNova Inc stock (US58468P2038): Biopharma innovator targeting unmet needs - AD HOC NEWS
TradingKey - TradingKey
What Medicinova (MNOV) is doing to earn customer loyalty (Tick Down) 2026-05-08Viral Momentum Stocks - newser.com
MediciNova Is Maintained at Buy by D. Boral Capital - Moomoo
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
Why are smart money investors paying attention to Medicinova (MNOV)? (Institutional Demand) 2026-05-03Popular Picks - newser.com
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest - MarketBeat
MediciNova Heads to ROTH, Puts Late-Stage Pipeline in Investor Spotlight - BriefGlance
MediciNova (NASDAQ: MNOV) proxy targets 247M authorized shares, board elections - Stock Titan
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Weekly Voice
New Peer‑Reviewed Study Reveals Actionable - GlobeNewswire
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - MSN
Researchers found a brain metastasis weakness — MediciNova plans clinical work - Stock Titan
MediciNova (NASDAQ: MNOV) to vote on 147M share increase, director slate - Stock Titan
Valuation Metrics Overview | Medicinova posts narrower than expected loss, 48.4% EPS beatShared Momentum Picks - Newser
MediciNova (MNOV) asks shareholders to approve 147M share increase ahead of June meeting - Stock Titan
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What is the bear case for Medicinova (MNOV) Stock | Price at $1.48, Down 1.01%Support Bounce - Xã Châu Thành
Gainers Report: What is the next catalyst for MediciNova IncMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Nasdaq Moves: Whats the MACD signal for MediciNova Inc2026 Spike Watch & Breakout Confirmation Trade Signals - baoquankhu1.vn
Fed Meeting: What is the next catalyst for MediciNova IncRecession Risk & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Investor Mood: What analysts say about MediciNova Inc stockSell Signal & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc expand its profit marginsQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
BYSI PE Ratio & Valuation, Is BYSI Overvalued - Intellectia AI
Sentiment Watch: How sensitive is MediciNova Inc to inflationWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Will Medicinova (MNOV) Stock Hit Record Highs | Price at $1.44, Up 1.41%Hull Moving Average - Newser
Buy Signal: What is the next catalyst for MediciNova IncEarnings Risk Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Winners Losers: Can MediciNova Inc beat the S P 500Forecast Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Medicinova Inc (NASDAQ:MNOV) Reiterates Buy Rating - FXDailyReport.Com
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova Inc stock draws attention amid biotech pipeline momentum and analyst upside calls - AD HOC NEWS
MediciNova (NASDAQ:MNOV) Upgraded at Zacks Research - Defense World
MediciNova (NASDAQ:MNOV) Raised to "Hold" at Zacks Research - MarketBeat
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):